Clinical Trial Update: Olaparib for PAH: a Multicenter Clinical Trial [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1/Phase 2 trial of olaparib for pulmonary arterial hypertension has been terminated. The sponsor is Laval University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Laval University | Conditions: Pulmonary Arterial Hypertension | Phase 1, Phase 2 | Status: TERMINATED